Literature DB >> 28487152

Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model.

Hyun Kuk Kim1, Myung Ho Jeong2, Kyung Seob Lim3, Jung Ha Kim3, Han Chul Lim3, Min Chul Kim3, Young Joon Hong3, Sung Soo Kim1, Keun-Ho Park1, Kyoung-Sig Chang1.   

Abstract

BACKGROUND: Several investigations have been conducted to evaluate the off-target effects of ticagrelor. The aim of the present study was to evaluate the off-target effects of ticagrelor such as neointimal formation and endothelial function after drug-eluting stent implantation in a porcine restenosis model.
METHODS: A total of 30 pigs were randomly allocated based on the following P2Y12 inhibitor: (1) clopidogrel 300mg loading plus 75mg maintenance (n=10); (2) prasugrel 60mg loading plus 10mg maintenance (n=10); (3) ticagrelor 180mg loading plus 180mg maintenance (n=10). In each group, zotarolimus-eluting stents were implanted in the proximal portion of the left anterior descending artery and left circumflex artery. One month after stenting, the animals underwent follow-up angiography, endothelial function assessment, optical coherence tomography (OCT) and histopathological analysis.
RESULTS: Regarding vasomotor responses to acetylcholine infusion, there were significant vasoconstrictions to maximal acetylcholine infusion in the clopidogrel and prasugrel group compared with those in the ticagrelor group. The mean neointimal area were significantly lower in the ticagrelor group (1.0±0.3 by OCT, 0.9±0.3 by histology), than in the clopidogrel (1.8±0.7, p=0.003, 1.6±0.8, p=0.030) and prasugrel (1.8±0.5, p=0.001, 1.5±0.5, p=0.019) groups. Percentages of moderate to dense peri-strut inflammatory cell infiltration were significantly lower in the ticagrelor group (9.0%) compared with the clopidogrel (17.3%, p<0.001) and prasugrel groups (15.7%, p=0.002). There were no significant differences in all findings between clopidogrel and prasugrel groups.
CONCLUSIONS: Compared to clopidogrel and prasugrel, ticagrelor reduced neointimal formation, endothelial dysfunction, and peri-strut inflammation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clopidogrel; Drug-eluting stents; Endothelium; Neointima formation; Prasugrel; Ticagrelor

Mesh:

Substances:

Year:  2017        PMID: 28487152     DOI: 10.1016/j.ijcard.2017.04.108

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  Interaction between platelets and endothelium: from pathophysiology to new therapeutic options.

Authors:  Michalis Hamilos; Stylianos Petousis; Fragiskos Parthenakis
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

2.  Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF).

Authors:  Francesco Vieceli Dalla Sega; Francesca Fortini; Giorgio Aquila; Rita Pavasini; Simone Biscaglia; Davide Bernucci; Annamaria Del Franco; Elisabetta Tonet; Paola Rizzo; Roberto Ferrari; Gianluca Campo
Journal:  Front Physiol       Date:  2018-04-06       Impact factor: 4.566

3.  Promoting vascular healing using nanofibrous ticagrelor-eluting stents.

Authors:  Cheng-Hung Lee; Ming-Jer Hsieh; Kuo-Sheng Liu; Che-Wei Cheng; Shang-Hung Chang; Shih-Jung Liu; Chao-Jan Wang; Ming-Yi Hsu; Kuo-Chun Hung; Yung-Hsin Yeh; Wei-Jan Chen; I-Chang Hsieh; Jyuhn-Huarng Juang; Ming-Shien Wen
Journal:  Int J Nanomedicine       Date:  2018-10-05

Review 4.  Endothelial Function: A Short Guide for the Interventional Cardiologist.

Authors:  Tommaso Gori
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

Review 5.  Platelets in In-stent Restenosis: From Fundamental Role to Possible Prognostic Application.

Authors:  Habib Haybar; Seyed M S Pezeshki; Najmaldin Saki
Journal:  Curr Cardiol Rev       Date:  2020

6.  No Differences in Levels of Circulating Progenitor Endothelial Cells or Circulating Endothelial Cells Among Patients Treated With Ticagrelor Compared With Clopidogrel During Non- ST -Segment-Elevation Myocardial Infarction.

Authors:  Alejandro Diego-Nieto; Maria B Vidriales; Norberto Alonso-Orcajo; Jose C Moreno-Samos; Francisco Martin-Herrero; Raul Carbonell; Belen Cid; Ignacio Cruz-Gonzalez; Javier C Martin-Moreiras; Carlos Cuellas; Cristina Pascual; Maria Lopez-Benito; Pedro L Sanchez; Felipe Fernandez-Vazquez; Armando Perez de Prado
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

7.  Beneficial Effects of Ticagrelor on Oxidized Low-Density Lipoprotein (ox-LDL)-Induced Apoptosis in Human Umbilical Vein Endothelial Cells.

Authors:  Meini Kang; Shuai Shao; Yue Zhang; Xue Liang; Kai Zhang; Guangping Li
Journal:  Med Sci Monit       Date:  2019-12-21

8.  Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk.

Authors:  Keun-Ho Park; Myung Ho Jeong; Hyun Kuk Kim; Young-Jae Ki; Sung Soo Kim; Dong-Hyun Choi; Young-Youp Koh; Youngkeun Ahn; Hyo-Soo Kim; Hyeon-Cheol Gwon; Seung-Woon Rha; Jin-Yong Hwang
Journal:  J Korean Med Sci       Date:  2021-11-01       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.